[The impact of the decrease of diurnal doses of insulin on main metabolic and anthropometric parameters in patients with DM2].
The aim of our investigation was to study the impact of the decrease of diurnal doses of insulin on main metabolic and anthropometric parameters in patients with DM2, who underwent the high diurnal doses of insulin. 36 patient with DM2 (mean age - 49,1+/-8,7 years) on high doses of insulin have been investigated. On the first stage the parameters of carbohydrate metabolism, HOMA-indices, parameters of lipid metabolism and blood pressure have been determined. I group consisted of 20 patients with decreased diurnal doses of insulin (from 65,6+/-19,3 units to 22,2+/-18,7 units), and II group - 16 patients with decreased diurnal doses of insulin (from 61,0+/-21,1 units to 45,3+/-7,5 units) and addition of metformin. After 6 months of treatment all parameters have been also determined. Fasting and postprandial glycemia and HbA(1C) levels were significantly decreased in both groups. C-peptide levels did not significantly change in I group. HOMA-%B and HOMA-%S indices significantly increased in both group, but the parameter of insulin resistance - HOMA-IR was significantly decreased only in II group. The improvement of dyslipidemia, hypertension and obesity was more expressed in II group. The positive changes in main metabolic and anthropometric parameters were more expressed in patients treatment tactics of whom consisted of insulin-sensitizing preparations.
D000273:Adipose Tissue; D000886:Anthropometry; D015992:Body Mass Index; D002940:Circadian Rhythm / Q000502:physiology*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006946:Hyperinsulinism / Q000453:epidemiology; D006949:Hyperlipidemias / Q000453:epidemiology; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use*; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged
D007004:Hypoglycemic Agents; D007328:Insulin